MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
0.3495
+0.0046
+1.33%
After Hours: 0.3543 +0.0048 +1.37% 19:30 09/09 EDT
OPEN
0.3452
PREV CLOSE
0.3449
HIGH
0.3557
LOW
0.3350
VOLUME
67.40K
TURNOVER
--
52 WEEK HIGH
77.70
52 WEEK LOW
0.3350
MARKET CAP
2.01M
P/E (TTM)
-0.0062
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLXN last week (0831-0904)?
Weekly Report · 2d ago
Silexion Posts Wider Q2 Loss On Higher SIL-204 Development Costs
NASDAQ · 5d ago
Weekly Report: what happened at SLXN last week (0824-0828)?
Weekly Report · 08/31 10:14
After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)
TipRanks · 08/25 13:00
Weekly Report: what happened at SLXN last week (0817-0821)?
Weekly Report · 08/24 10:14
Silexion Therapeutics Receives Nasdaq Delisting Notice, Plans Appeal
TipRanks · 08/21 21:03
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)
TipRanks · 08/19 16:30
Weekly Report: what happened at SLXN last week (0810-0814)?
Weekly Report · 08/17 10:15
More
About SLXN
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.